Literature DB >> 2873213

Cyclic GMP as mediator and biological marker of atrial natriuretic factor.

P Hamet, J Tremblay, S C Pang, R Skuherska, E L Schiffrin, R Garcia, M Cantin, J Genest, R Palmour, F R Ervin.   

Abstract

Both our previous and the present studies established that increases in cyclic guanosine monophosphate (cGMP) reflect the activity of atrial natriuretic factor (ANF). The ANF message is transmitted by particulate guanylate cyclase, which appears to be in intimate contact with the ANF receptor since stimulation of particulate guanylate cyclase is observed even after dispersion of the membranes. The stimulation of smooth muscle and endothelial cells in culture leads to egression of cGMP to extracellular medium where it accumulates for over 2 h. The signal of the extracellular cGMP is magnified and prolonged compared to the intracellular signal. The stimulation of cGMP production by ANF in vascular smooth muscle and endothelial cells appears to be relatively irreversible and the responsiveness is down-regulated by prior exposure to low doses of ANF. Cyclic guanosine monophosphate can also serve as a marker for ANF action. Atrial natriuretic factor fragments of different potencies exert a biological activity that correlates with ANF-induced cGMP increases. In hypertensive rats and monkeys, where acute infusion of ANF leads to an exaggerated diuresis and natriuresis, urinary cGMP does not appear to be different. Overall, cGMP appears to be a mediator and a marker of ANF biological activity and may serve as a useful tool in the study of pathogenesis of hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873213

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  24 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Particulate guanylate cyclase and adenylate cyclase activities after activation with various agents in rabbit platelets. An ultracytochemical study.

Authors:  A Spreca; M G Rambotti; R Donato
Journal:  Histochem J       Date:  1991-03

3.  Immunoreactive atrial and brain natriuretic peptides are co-localized in Purkinje fibres but not in the innervation of the bovine heart conduction system.

Authors:  M Hansson; S Forsgren
Journal:  Histochem J       Date:  1995-03

Review 4.  Receptor sites for atrial natriuretic factors in brain and associated structures: an overview.

Authors:  R Quirion
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

5.  Presence of immunoreactive atrial natriuretic peptide in nerve fibres and conduction cells in the conduction system of the bovine heart.

Authors:  M Hansson; S Forsgren
Journal:  Anat Embryol (Berl)       Date:  1993-10

6.  Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene.

Authors:  Y Ogawa; H Itoh; N Tamura; S Suga; T Yoshimasa; M Uehira; S Matsuda; S Shiono; H Nishimoto; K Nakao
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  Inhibitory effects of guanosine 3':5'-cyclic monophosphate on the synthesis of dopamine in the rat kidney.

Authors:  P Soares-da-Silva; M H Fernandes
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

9.  The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system.

Authors:  M B Anand-Srivastava; J Gutkowska; M Cantin
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.